Major Players - Human Insulin Drug Industry

Over the course of the forecast period, it is anticipated that the prevalence of diabetes (including type 1 and type 2 diabetes) would rise globally. Diabetes is a significant risk factor for renal failure, heart attacks, strokes, blindness, and lower limb amputation. Compared to high-income countries, the prevalence of diabetes has been increasing more quickly in low- and middle-income nations. The bulk of the world's 422 million diabetics live in low- and middle-income countries, and diabetes is directly responsible for 1.5 million fatalities annually, according to the World Health Organisation (WHO).

Over the course of the projected period, an increase in demand for human insulin medicines to treat diabetes is anticipated to boost market expansion. For instance, the demand for human insulin medications is rising quickly along with the prevalence of diabetes (both type 1 and type 2 diabetes). Novo Nordisk announced the introduction of oral semaglutide for the treatment of type 2 diabetes in India in January 2022. Glucagon-like peptide (GLP-1) receptor analogue oral semaglutide is a promising supplement to the treatment of diabetes. The medicine was only offered in injection form up until this point.

The market for Human Insulin Drugs was valued at US$ 42,283.9 million in 2021 and is anticipated to grow at a CAGR of 8.1% from 2022 to 2028 to reach US$ 73,127.2 million.

1.  Wockhardt:

 An important pharmaceutical manufacturer with an emphasis on biotechnology and pharmaceutical products is Wockhardt Ltd. The corporation manages its chain of Super Specialty Hospitals in addition to conducting research in the pharmaceutical and biotechnology industries. head office in Mumbai.

2.  Exir:

  Built in 1988.Iranian pharmaceutical firm Exir Pharmaceutical Co. In addition to tablets, capsules, ampoules, cartridges, syrups, powder for oral suspension, and injectable vials, it also makes pharmaceuticals in other dosage forms.

3.   Julphar:

  central office in Bangladesh. Pharmaceutical medicine producer for the health sector. The company's facilities are strong in general manufacturing, a unit dedicated to cephalosporins, advanced three layer floors, prototype R & D laboratories, effluent treatment plant (ETP), and an advanced water treatment system with recycling facilities, which allows it to meet the needs of clients who need generic drugs. Founded 2009.

4.  Biocon:

  A biopharmaceutical business called Biocon Ltd. creates biotechnology treatments for illnesses. The company's main areas of concentration include the development, production, and supply of innovative and biosimilar medications for autoimmune diseases, cancer, and diabetes. Established in 1978. Head office in Karnataka.

5.  Eli Lilly:

Eli Lilly is a pharmaceutical company with a focus on immunology, cancer, cardiometabolic disease, and neuroscience. Verzenio for cancer, Mounjaro, Jardiance, Trulicity, Humalog, and Humulin for diabetes, Taltz, and Olumiant for immunology are some of Lilly's most important pharmaceuticals. Built in 1875. U.S. headquarters are in Indianapolis

6.   Sanofi Aventis:

Sanofi S.A. is a multinational pharmaceutical company that engages in the research and development, of pharmacological products, in the prescription market. The firm cover therapeutic areas like Cardiovascular, central nervous system, diabetes, internal medicine. The company was founded in 973 and the headquarters are located in Paris, France. Products manufactured include Medications, Genetic drugs, Vaccines, Animal Health, etc. December, 2022 Sanofi expanded its collaboration with Innate Pharma, with Sanofi licensing a natural killer (NK) cell nagger program targeting B7H3 from Innate’s ANKET platform.

7.  Novo Nordisk AS:

 Novartis AG is a Swiss pharmaceutical corporation founded in March 1996 by Johann Rudolf The headquarters are located in Basel Switzerland, Cambridge, The United States of America and Massachusetts. It is one of the largest Pharma based company incorporated. The drugs manufactured are sold worldwide. Total revenue earned as of 2022 is US 50.545 billion dollars. In June, 2022 Novartis completed the acquisition of Kedalion Therapeutics and its AcuStream technology

*Definition: 

insulin is used to control blood sugar in people with type 1 diabetes and type 2 diabetes. Insulin is mostly used to treat type 1 diabetes, but can be used in people with type 2 diabetes if insulin levels remain low despite the use of other types of drugs.